Septerna, Inc. Increase (Decrease) in Other Operating Assets
Septerna, Inc. (SEPN) reported Increase (Decrease) in Other Operating Assets of $414.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-10
- Septerna, Inc. increase (decrease) in other operating assets for the quarter ending 2026-06-30 was $457.00K, a 1804.17% increase year-over-year.
- Septerna, Inc. increase (decrease) in other operating assets for the quarter ending 2026-03-31 was -$43.00K, a 577.78% decline year-over-year.
- Septerna, Inc. increase (decrease) in other operating assets for the quarter ending 2025-12-31 was $316.00K.
- Septerna, Inc. increase (decrease) in other operating assets for the quarter ending 2025-09-30 was $205.00K, a 10.81% increase year-over-year.
- Septerna, Inc. increase (decrease) in other operating assets for fiscal 2025 was $554.00K, a 225.88% increase from fiscal 2024.
- Septerna, Inc. increase (decrease) in other operating assets for fiscal 2024 was $170.00K.
- Septerna, Inc. increase (decrease) in other operating assets for fiscal 2023 was -$165.00K.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $457.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $414.00K 10-Q · filed 2026-08-10 | $730.00K derived: sum of 3 quarters · filed 2026-08-10 | $935.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$43.00K 10-Q · filed 2026-05-11 | $273.00K derived: sum of 2 quarters · filed 2026-05-11 | $478.00K derived: sum of 3 quarters · filed 2026-05-11 | $502.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $316.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $521.00K derived: sum of 2 quarters · filed 2026-03-09 | $545.00K derived: sum of 3 quarters · filed 2026-08-10 | $554.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | $205.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $229.00K derived: sum of 2 quarters · filed 2026-08-10 | $238.00K 10-Q · filed 2025-11-10 | $235.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $33.00K 10-Q · filed 2026-08-10 | $30.00K derived: sum of 3 quarters · filed 2026-08-10 | $215.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $9.00K 10-Q · filed 2026-05-11 | $6.00K derived: sum of 2 quarters · filed 2026-05-11 | $191.00K derived: sum of 3 quarters · filed 2026-05-11 | $155.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $182.00K derived: sum of 2 quarters · filed 2026-03-09 | $146.00K derived: sum of 3 quarters · filed 2026-03-09 | $170.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $185.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $149.00K derived: sum of 2 quarters · filed 2025-11-10 | $173.00K 10-Q · filed 2025-11-10 | -$207.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$12.00K 10-Q · filed 2025-08-11 | -$392.00K derived: sum of 3 quarters · filed 2025-08-11 | |
| 2024-03-31 | $24.00K 10-Q · filed 2025-05-15 | -$356.00K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$380.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$165.00K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $215.00K 10-Q · filed 2024-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |